Company Profile
Moderna Therapeutics
Company Overview
Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions.
Moderna has developed a broad intellectual property estate, including more than 320 patent applications covering novel nucleotide chemistries and drug compositions. The company plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as new formed ventures.
Founded by Flagship VentureLabs™, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals, and Merck.
Company History
Invention is our culture, and we are in a unique position of pioneering an entirely new field. From the outset of the company’s founding, we have focused on building a dominant intellectual property estate, and have met the quantum potential of messenger RNA Therapeutics™ by developing an IP portfolio that will allow us to freely conduct our activities, protect our valuable assets, and maintain our exclusive rights.
One of our earliest priorities was the establishment of a multi-disciplinary, experienced, and creative intellectual property team who are passionate, and who think big. Our patent portfolio reflects this mindset: we have implemented a thorough and comprehensive intellectual property strategy, having filed 144 patent applications reciting 6,910 claims directed to the company’s technology platform and drug discovery and development programs, including novel chemical modifications, RNA engineering, formulation, composition of matter, route of administration, and dosing paradigms.
That’s just the beginning.